URGN UroGen Pharma Ltd

$URGN according to my source, the sales team made their numbers and Moore for ZUSDURI expect to see over 90 million for the quarter

$URGN I am a believer that this co will be taken out above $100 sometime next year. So this heavy drop, 1 month before ER call, could be funds positioning themselves for a big rise. Shake the tree, collect the fruit, then eat.

$URGN Q3 predictions: Zusduri net rev of $75 mil Jelmyto net rev of $26 mil Company will actually turn a profit for the quarter. Stock price should rise but who really knows? GLTA.

$URGN Sure looks like manipulation to me. This should do nothing but go up to analysts PTs before a drop like this. 12.78% SI may have something to do with it. Buy'em Extremely

Oppenheimer reiterated $URGN Outperform-$60 after hosting the Co. for non-deal roadshow meetings in Denver and Los Angeles last week and coming away more confident in Zusduri's commercial opportunity. [CGON TYRA JNJ TARA MRK LLY IBRX] Oppenheimer said in its note: Management continues to expect essentially linear quarterly growth through 2026, and we see potential for inflection next year off planned DTC marketing. Launch momentum should more than offset any seasonal headwind from lighter 3Q procedure volumes; we maintain our above-consensus $66.0M estimate. We believe the patient and provider incentives favoring Zusduri over surgery remain underappreciated. With fewer than 10% of ~6,500 targeted physicians having tried the product, early adopters poised to broaden use, and favorable reimbursement, our confidence in our 2030E peak sales forecast of $1.2B has increased.

$URGN Short interest dropped over 2.1m shares from 7.77m to 5.61m as of the 15th. Hopefully this will help us get going in the right direction.

$URGN I remember reading the below and thinking this guy is full of it at that price...well, whether luck or skill, it took a bit more than a few days but here were are in the "mid to low 30s". Take a bow.

$URGN 🏥 UroGen Pharma Ltd. announced FDA acceptance of its New Drug Application for UGN-103 (mitomycin) for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, with a PDUFA target action date of June 14, 2027. Market-relevant event

$URGN What could have possibly happened to warrant this? Will we be getting bad news AH?

Latest company news, October 19, 2026: The FDA accepted UroGen's NDA for UGN-103 in recurrent low-grade intermediate-risk NMIBC, with a PDUFA target action date of June 14, 2027. UroGen ($URGN): Can ZUSDURI Growth Turn Into Cash? Deeper dive in our hub. Not investment advice.

$URGN (UroGen Pharma, maker of the bladder-cancer drug ZUSDURI) has a June 14, 2027 FDA target action date for UGN-103, its next-gen mitomycin gel, after the agency accepted the NDA. It targets ZUSDURI's recurrent LG-IR-NMIBC use; ZUSDURI sold $50.4M in Q2 2026, vs. a ~$1.69B market value at $34.56, the October 16, 2026 close (16:00 ET). But it mostly extends that franchise (patents expected into July 2044) rather than opening a new market, and the date could slip. After any approval, full launch waits on a unique J-Code.